Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-05
2009-11-10
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S526000
Reexamination Certificate
active
07615573
ABSTRACT:
Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
REFERENCES:
patent: 5631394 (1997-05-01), Wei et al.
patent: 5707649 (1998-01-01), Inokuchi et al.
patent: 5763438 (1998-06-01), Inokuchi et al.
patent: 5849326 (1998-12-01), Inokuchi et al.
patent: 5907039 (1999-05-01), Jinbo et al.
patent: 5916911 (1999-06-01), Shayman et al.
patent: 5945442 (1999-08-01), Shayman et al.
patent: 5952370 (1999-09-01), Shayman et al.
patent: 5972928 (1999-10-01), Chatterjee
patent: 6030995 (2000-02-01), Shayman et al.
patent: 6040332 (2000-03-01), Shayman et al.
patent: 6051598 (2000-04-01), Shayman et al.
patent: 6228889 (2001-05-01), Chatterjee
patent: 6255336 (2001-07-01), Shayman et al.
patent: 6335444 (2002-01-01), Jinbo et al.
patent: 6511979 (2003-01-01), Chatterjee
patent: 6569889 (2003-05-01), Shayman et al.
patent: 6855830 (2005-02-01), Hirth et al.
patent: 6890949 (2005-05-01), Shayman et al.
patent: 6916802 (2005-07-01), Shayman et al.
patent: 7148251 (2006-12-01), Shayman et al.
patent: 7196205 (2007-03-01), Siegel et al.
patent: 7253185 (2007-08-01), Shayman et al.
patent: 7265228 (2007-09-01), Hirth et al.
patent: 2002/0198240 (2002-12-01), Shayman et al.
patent: 2003/0073680 (2003-04-01), Shayman et al.
patent: 2004/0260099 (2004-12-01), Shayman
patent: 2005/0239862 (2005-10-01), Shayman et al.
patent: 2006/0217560 (2006-09-01), Shayman
patent: 2007/0072916 (2007-03-01), Shayman
patent: 126974 (1984-12-01), None
patent: 1 384 719 (2004-01-01), None
patent: 9-169664 (1997-06-01), None
patent: 9216856 (1997-08-01), None
patent: 10324671 (1998-12-01), None
patent: 10338636 (1998-12-01), None
patent: WO 97/10817 (1997-03-01), None
patent: WO 98/52553 (1998-11-01), None
patent: WO 01/04108 (2001-01-01), None
patent: WO 02/062777 (2002-08-01), None
patent: WO 03/008399 (2003-01-01), None
patent: WO 2007/134086 (2007-11-01), None
Zhao et al., Diabetes, vol. 56, May 2007, pp. 1210-1218.
Abdel-Magid, A., et al., “Metal-Assisted Aldol Condensation of Chiral α-Halogenated Imide Enolates: A Stereocontrolled Chiral Epoxide Synthesis,”J. Am. Chem. Soc., 108: 4595-4602 (1986).
Abe, A., et al., “Improved Inhibitors of Glucosylceramide Synthase,”J. Biochem., 111: 191-196 (1992).
Abe, A., et al., “Induction of Glucosylceramide Synthase by Synthase Inhibitors and Ceramide,”Biochim. Biophys. Acta, 1299: 333-341 (1996).
Abe, A., et al., “Metabolic Effects of Short-Chain Ceramide and Glucosylceramide on Sphingolipids and Protein Kinase C,”Eur. J. Biochem., 210: 765-773 (1992).
Abe, A., et al., “Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth,”J. of Lipid Research, 36: 611-621 (1995).
Alker, D., et al., “Application of Enantiopure Templated Azomethine Ylids to β-Hydroxy-α-amino Acid Synthesis,”Tetrahedron: Asymmetry, 54: 6089-6098 (1998).
Alon, R., et al., “Glycolipid Ligands for Selectins Support Leukocyte Tethering and Rolling Under Physiologic Flow Conditions,”J. Immunol., 154: 5356-5366 (1995).
Ames, Bruce N., “Assay of Inorganic Phosphate, Total Phosphate and Phosphatases,”Methods Enzymol., 8: 115-118(1966).
Bielawska, A., et al., “Ceramide-Mediated Biology: Determination of Structural and Stereospecific Requirements Through the Use ofN-Acyl-Phenylaminoalcohol Analogs,” .J. Biol. Chem., 267: 18493-18497 (1992).
Bielawska, A., et al., “Modulation of Cell Growth and Differentiation by Ceramide,”FEBS Letters, 307(2): 211-214(1992).
Blobe, G. C., et al., “Regulation of Protein Kinase C and Role in Cancer Biology,”Cancer Metastasis Rev., 13: 411-431 (1994).
Brenkert, A., et al., “Synthesis of Galactosyl Ceramide and Glucosyl Ceramide by Rat Brain: Assay Procedures and Changes with Age,”Brain Res., 36: 183-193 (1972).
Carson, K.G., et al., “Studies on Morpholinosphingolipids: Potent Inhibitors of Glucosylceramide Synthase,”Tetrahedron Letters, 35(17): 2659-2662 (1994).
Dellaria, Jr., J.F., et al., “Enantioselective Synthesis of α-Amino Acid Derivatives via the Stereoselective Alkylation of a Homochiral Glycine Enolate Synthon,”J. Org. Chem., 54: 3916-3926 (1989).
Evans, D. A., et al., “Stereoselective Aldol Condensations Via Boron Enolates,” .J. Am. Chem. Soc., 103: 3099-3111 (1981).
Felding-Habermann, B., et al., “A Ceramide Analog Inhibits T Cell Proliferative Response Through Inhibition of Glycosphingolipid Synthesis and Enhancement ofN, N-Dimethylsphingosine Synthesis,”Biochemistry, 29: 6314-6322 (1990).
Gatt, S., et al., “Assay of Enzymes of Lipid Metabolism With Colored and Fluorescent Derivatives of Natural Lipids,”Meth. Enzymol., 72: 351-375 (1981).
Hakomori, S., “New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-Adhesion and Ortho-Signaling Therapy,”Cancer Cells, 3(12): 461-470 (1991).
Hammett, L. P.,Physical Organic Chemistry, (NY: McGraw-Hill), (1940).
Harwood, L.M., et al., “Asymmetric Cycloadditions of Aldehydes to Stabilized Azomethine Ylids: Enantiocontrolled Construction of β-Hydroxy-α-amino acid Derivitives,”Tetrahedron: Asymmetry, 3(9): 1127-1130 (1992).
Harwood, L.M., et al., “Double diastereocontrol in the synthesis of enantiomerically pure polyoxamic acid,”Chem. Commun., 2641-2642 (1998).
Högberg, T., et al., “Theoretical and Experimental Methods in Drug Design Applied on Antipsychotic Dopamine Antagonists.” InTextbook of Drug Design and Development, pp. 55-91 (1991).
Hospattankar, A. V., et al., “Changes in Liver Lipids After Administration of 2-Decanoylamino-3-Morpholinopropiophenone and Chlorpromazine,”Lipids, 17(8): 538-543 (1982).
Inokuchi, J., et al., “Antitumor Activity: Via Inhibition of Glycosphingolipid Biosynthesis,”Cancer Letters, 38: 23-30 (1987).
Inokuchi, J., et al., “Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glucosylceramide Synthase and Its Possible Mechanism of Action,”Cancer Res., 50: 6731-6737 (1990).
Inokuchi, J., et al., “Preparation of the active isomer of 1-pheny1-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase,”J. of Lipid Research, 28: 565-571 (1987).
Jaffrézou, J., et al., “Inhibition of Lysosomal Acid Sphingomyelinase by Agents which Reverse Multidrug Resistance,”Biochim. Biophys. Acta, 1266: 1-8 (1995).
Kalén, A., et al., “Elevated Ceramide Levels in GH4C1Cells Treated with Retinoic Acid,”Biochim. Biophys. Acta, 1125: 90-96 (1992).
Kopaczyk, K. C., et al., “In Vivo Conversions of Cerebroside and Ceramide in Rat Brain,”J. Lipid Res., 6: 140-145 (1965).
Kurosawa, M., et al., “C-Labeling of a Novel Atypical β-Adrenoceptor Agonist, SM-11044,”Journal of Labelled Compounds and Radiopharmaceuticals, 38(3): 285-297 (1996).
Lee, L., et al., “Improved Inhibitors of Glucosylceramide Synthase,”J. Biol. Chem., 274(21): 14662-14669 (1999).
Mitchell, S.A., et al., “Glycosyltransferase Inhibitors: Synthesis of D-threo-PDMP, L-threo-PDMP, and Other Brain Glucosylceramide Synthase Inhibitors from D- or L-Serine,”J. Org. Chem., 63: 8837-8842 (1998).
Nakamura, K., et al., “Coomassie Brilliant Blue Staining of Lipids on Thin-Layer Plates,”Anal. Biochem., 142: 406-410 (1984).
Nicolaou, K.C., et al., “A Practical and Enantioselective Synthesis of Glycosphingolipids and Related Compounds. Total Synthesis of Globotriaosylceramide (Gb3),”J. Am. Chem. Soc., 110: 7910-7912 (1988).
Nishida, A., et al., “Practical Synthesis ofthreo-(1S, 2S)- anderythro-(1R, 2S)-1-Pheny1-2- palmitoylamino-3-morpholino-1-propanol (PPMP) from L-Serine,”Sy
Copeland Diane P.
Harris David J.
Nelson Carol A.
Shayman James A.
Siegel Craig
Anderson Rebecca L
Davis Steven G.
Foley & Lardner LLP
Genzyme Corporation
The Regents of the University of Michigan
LandOfFree
Synthesis of UDP-glucose: N-acylsphingosine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of UDP-glucose: N-acylsphingosine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of UDP-glucose: N-acylsphingosine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4144228